Cover Image
市場調查報告書

唾液腺癌:開發平台分析

Salivary Gland Cancer - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213098
出版日期 內容資訊 英文 104 Pages
訂單完成後即時交付
價格
Back to Top
唾液腺癌:開發平台分析 Salivary Gland Cancer - Pipeline Review, H2 2016
出版日期: 2016年11月16日 內容資訊: 英文 104 Pages
簡介

唾液腺癌是唾液腺發病的罕見癌症。唾液腺癌會發病於口部、頸部、喉頭唾液腺的任何部位。症狀有下巴及頸部、口部周圍的疙瘩,臉部部分麻痺、吞嚥困難、嘴巴無法大開等。危險因子包含了年齡、曝露在放射線中。

本報告提供唾液腺癌的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等相關的系統性資訊。

目錄

簡介

唾液腺癌概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 臨床階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

開發治療藥的企業

  • Bayer AG
  • Ignyta, Inc.
  • Loxo Oncology, Inc.
  • 大塚集團
  • Plexxikon Inc.
  • Taiwan Liposome Company, Ltd.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

開發中產品的最新趨勢

暫停中的計劃

開發中止的產品

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8681IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Salivary Gland Cancer - Pipeline Review, H2 2016, provides an overview of the Salivary Gland Cancer (Oncology) pipeline landscape.

Salivary gland cancer is a rare form of cancer that begins in the salivary glands. Salivary gland cancer can begin in any of the salivary glands in mouth, neck or throat. Symptoms include a lump or swelling on or near jaw or in neck or mouth, numbness in part of face, difficulty swallowing and trouble opening mouth widely. Risk factors include age and radiation exposure.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Salivary Gland Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Salivary Gland Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Salivary Gland Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Salivary Gland Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 1, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.Salivary Gland Cancer.

Salivary Gland Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Salivary Gland Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Salivary Gland Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Salivary Gland Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Salivary Gland Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Salivary Gland Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Salivary Gland Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Salivary Gland Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Salivary Gland Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Salivary Gland Cancer - Overview
    • Pipeline Products for Salivary Gland Cancer - Comparative Analysis
  • Salivary Gland Cancer - Therapeutics under Development by Companies
  • Salivary Gland Cancer - Therapeutics under Investigation by Universities/Institutes
  • Salivary Gland Cancer - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
  • Salivary Gland Cancer - Products under Development by Companies
  • Salivary Gland Cancer - Products under Investigation by Universities/Institutes
  • Salivary Gland Cancer - Companies Involved in Therapeutics Development
    • Bayer AG
    • Ignyta, Inc.
    • Johnson & Johnson
    • Loxo Oncology, Inc.
    • Merck & Co., Inc.
    • Plexxikon Inc.
    • Taiwan Liposome Company, Ltd.
  • Salivary Gland Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Cellular Immunotherapy for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • entrectinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LOXO-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pembrolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pexidartinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • regorafenib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tipifarnib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TLC-388 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target WT1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Salivary Gland Cancer - Dormant Projects
  • Salivary Gland Cancer - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Salivary Gland Cancer, H2 2016
  • Number of Products under Development for Salivary Gland Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Salivary Gland Cancer - Pipeline by Bayer AG, H2 2016
  • Salivary Gland Cancer - Pipeline by Ignyta, Inc., H2 2016
  • Salivary Gland Cancer - Pipeline by Johnson & Johnson, H2 2016
  • Salivary Gland Cancer - Pipeline by Loxo Oncology, Inc., H2 2016
  • Salivary Gland Cancer - Pipeline by Merck & Co., Inc., H2 2016
  • Salivary Gland Cancer - Pipeline by Plexxikon Inc., H2 2016
  • Salivary Gland Cancer - Pipeline by Taiwan Liposome Company, Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Salivary Gland Cancer - Dormant Projects, H2 2016
  • Salivary Gland Cancer - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Salivary Gland Cancer, H2 2016
  • Number of Products under Development for Salivary Gland Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top